$IMCR
$37.40
+$1.27 (3.52%)
Immunocore Holdings plc
immunocore.comImmunocore Holdings PLC (NASDAQ: IMCR) is a clinical-stage biopharmaceutical company that develops T cell receptor-based therapies for the treatment of cancer and infectious diseases. The filing excerpts provided do not contain sufficient detail to describe its revenue model, approved products, commercial stage, geographic footprint, competitive position, leadership, or financial metrics. Based solely on the available excerpts, no further factual claims can be supported.
Financial Snapshot
Revenue
TTM
$430.8M
Gross Margin
TTM
98.89%
Net Income
TTM
-$18.07M
Current Assets
2026 Q2
Current Liabilities
2026 Q2
Current Ratio
2026 Q2
446.88%
Total Assets
2026 Q2
Total Liabilities
2026 Q2
Book Value
2026 Q2
$419.8M
Cash
2026 Q2
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$41.15M
Loading...
